HIV-1 Resistance (Protease and reverse transcriptase)
Decreased susceptibility of HIV-1 to antiretroviral drugs is usually associated with sequence changes in the viral genome (genotypic drug resistance). Detection of these mutations in the viral genome can be used to predict accurately the susceptibility of the virus to all currently licensed antiretroviral drugs and thus can be used to optimise the use of antiretroviral treatment on an individual patient basis. The routine test for resistance to protease and reverse-transcriptase inhibitors generates a sequence covering the resistance associate sites in the protease and the reverse-transcriptase gene.
Baseline and/or when failing therapy
Please contact the laboratory.
|Sample & container required||Plasma or Serum|
|Turnaround time||14 days|
Must have quantifiable HIV-1 viral load.
This assay has changed to the Vela NGS assay is currently awaiting UKAS accreditation.